Vanguard Group Inc Cue Biopharma, Inc. Transaction History

Vanguard Group Inc

$5.12 Trillion
Q2 2024

A detailed history of Vanguard Group Inc transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,031,421 shares of CUE stock, worth $3.03 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,031,421

Previous 2,283,362 11.03%

Holding current value

$3.03 Million

Previous $4.32 Million 41.65%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$1.24 - $2.18 $312,406 - $549,231	-251,941 Reduced 11.03%	2,031,421 $2.52 Million
Q1 2024 May 10, 2024	BUY	$1.77 - $3.09 $266,308 - $464,912	150,457 Added 7.05%	2,283,362 $4.32 Million
Q4 2023 Feb 14, 2024	BUY	$1.72 - $3.1 $13,758 - $24,796	7,999 Added 0.38%	2,132,905 $5.63 Million
Q3 2023 Nov 14, 2023	BUY	$2.23 - $4.69 $170,331 - $358,231	76,382 Added 3.73%	2,124,906 $4.89 Million
Q2 2023 Aug 14, 2023	BUY	$3.11 - $4.91 $1.23 Million - $1.94 Million	394,928 Added 23.88%	2,048,524 $7.48 Million
Q1 2023 May 15, 2023	BUY	$2.41 - $3.74 $300,445 - $466,250	124,666 Added 8.15%	1,653,596 $5.9 Million
Q4 2022 Feb 10, 2023	BUY	$2.39 - $3.95 $15,800 - $26,113	6,611 Added 0.43%	1,528,930 $4.36 Million
Q2 2022 Aug 12, 2022	SELL	$2.49 - $5.92 $327,230 - $777,994	-131,418 Reduced 7.95%	1,522,319 $3.79 Million
Q1 2022 May 13, 2022	BUY	$4.41 - $12.28 $451,685 - $1.26 Million	102,423 Added 6.6%	1,653,737 $8.07 Million
Q4 2021 Feb 14, 2022	SELL	$10.86 - $17.85 $243,329 - $399,947	-22,406 Reduced 1.42%	1,551,314 $17.5 Million
Q3 2021 Nov 12, 2021	BUY	$10.06 - $15.3 $160,980 - $244,830	16,002 Added 1.03%	1,573,720 $22.9 Million
Q2 2021 Aug 13, 2021	BUY	$10.9 - $14.53 $17 Million - $22.6 Million	1,557,718 New	1,557,718 $18.1 Million

Others Institutions Holding CUE

# of Institutions

Shares Held

13.9M

Call Options Held

56.1K

Put Options Held

11.1K

View Full List

About Cue Biopharma, Inc.

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $52.7M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

More about CUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Cue Biopharma, Inc. Transaction History